Skip to main content
Year archive

Ipsen — 2026 filings

All 32 regulatory filings released by Ipsen (IPN) in 2026, sourced directly from the official regulator.

32 Filings
2026 Period
2026 filings (32)
Filing Released Lang
Ipsen enregistre une forte croissance de ses ventes au premier trimestre 2026 et confirme ses objectifs annuels
Earnings Release Q1 2026
2026-04-23 French
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
Earnings Release Q1 2026
2026-04-23 English
Ipsen S.A. - Informations concernant la tenue de l’Assemblée Générale Mixte du 13 mai 2026
Regulatory Filings
2026-04-22 French
Ipsen S.A. - Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026
Proxy Solicitation & Information Statement
2026-04-22 English
Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer
M&A Activity
2026-04-03 English
Ipsen annonce l’obtention par Beech Tree d’une dérogation à l’obligation de déposer une offre publique
Regulatory Filings
2026-04-03 French
Ipsen annonce la mise à disposition de son Document d’enregistrement universel 2025
Report Publication Announcement
2026-04-01 French
Ipsen announces the availability of its 2025 Universal Registration Document
Report Publication Announcement
2026-04-01 English
Ipsen - Février 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Regulatory Filings
2026-03-13 French
Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
Regulatory Filings
2026-03-13 English
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
Regulatory Filings
2026-03-09 English
Update: Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde
Regulatory Filings
2026-03-09 French
Ipsen S.A. publie ses comptes consolidés 2025
Audit Report / Information FY 2025
2026-02-19 French
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
Interim / Quarterly Report FY 2025
2026-02-19 English
Ipsen réalise de solides résultats en 2025, grâce à une performance soutenue de toutes les aires thérapeutiques, et annonce ses objectifs 2026
Earnings Release FY 2025
2026-02-12 French
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
Earnings Release FY 2025
2026-02-12 English
Ipsen - Janvier 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Regulatory Filings
2026-02-09 French
Ipsen - January 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
Regulatory Filings
2026-02-09 English
Ipsen nominates Peter Guenter to its Board of Directors
Board/Management Information
2026-01-29 English
Ipsen nomme Peter Guenter au sein de son Conseil d’Administration
Board/Management Information
2026-01-29 French
Pierrick Lefranc nommé Vice-Président Exécutif Opérations Techniques et membre du Comité Exécutif
Board/Management Information
2026-01-27 French
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
Board/Management Information
2026-01-27 English
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
Legal Proceedings Report
2026-01-21 English
Le tribunal arbitral confirme la résiliation par Ipsen de l'accord de R&D conclu avec Galderma
Legal Proceedings Report
2026-01-21 French
De nouvelles données renforcent l’engagement d’Ipsen à proposer des solutions et à combler les lacunes de prise en charge dans les maladies neurologiques lors du congrès TOXINS
Regulatory Filings
2026-01-14 French
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
Regulatory Filings
2026-01-14 English
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
Regulatory Filings
2026-01-13 English
La FDA américaine accorde la désignation « Breakthrough Therapy » à l’IPN60340 (ICT01) d’Ipsen dans la leucémie myéloïde aiguë de première ligne chez les patients inéligibles à une chimiothérapie int
Regulatory Filings
2026-01-13 French
Ipsen - Décembre 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2026-01-07 French
Ipsen - December 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Share Issue/Capital Change
2026-01-07 English
Ipsen – Half year statement – 2025 12 31
Transaction in Own Shares
2026-01-06 English
Ipsen - Bilan semestriel - 31 12 2025
Transaction in Own Shares
2026-01-06 French